GET DAILY SIGNALScbdMD (YCBD): Building a Diversified Wellness Portfolio Through Strategic Moves
Key Takeaways
- YCBD is the ticker for cbdMD, Inc., a U.S.-based consumer wellness and hemp-derived CBD company listed on the NYSE American exchange.
- The company markets several brands, including cbdMD, Paw CBD, Bluebird Botanicals, ATRx Labs, and the Herbal Oasis THC beverage line.
- cbdMD recently acquired the operating assets of Twinlab, adding legacy supplement brands such as Twinlab, Reserveage, and Metabolife to diversify beyond hemp.
- Revenue is generated primarily through direct-to-consumer e-commerce, online marketplaces, and wholesale distribution to brick-and-mortar retailers.
- The company operates in a heavily regulated industry, making federal and state hemp and CBD rules a central risk factor for its business.
Getting to Know cbdMD
cbdMD, Inc. develops, markets, and distributes hemp-derived CBD products along with other wellness offerings. Traded under the ticker YCBD, the company is based in Charlotte, North Carolina, and centers its efforts on the cbdMD brand of tinctures, gummies, capsules, and topicals. From what I see, investors track the firm for its place in the CBD and wellness markets, its collection of established brands, and its steps to expand beyond hemp-derived items.
Company Background and Operations
cbdMD, Inc. was established in North Carolina in March 2015, originally as Level Beauty Group, Inc., then Level Brands, Inc., before taking on the cbdMD name in May 2019. CEO and CFO T. Ronan Kennedy leads the company, which employs roughly 42 people and maintains its main offices in Charlotte.
The business focuses on creating and selling branded wellness items through multiple channels. The core cbdMD line features broad and full spectrum CBD products such as tinctures, gummies, topicals, capsules, and aids for sleep, focus, and calm. Paw CBD targets pets with veterinarian-formulated options, while ATRx Labs provides functional mushroom supplements for immunity, focus, digestive health, and mood. Herbal Oasis includes hemp-derived, THC-infused social seltzers, and Bluebird Botanicals offers premium full spectrum CBD products.
In late 2026, cbdMD finished acquiring the operating assets of Twinlab. This added the Twinlab, Reserveage, Metabolife, and ResVitale supplement brands to the mix, representing a clear step to broaden the portfolio past hemp and build strength in vitamins, nutritional supplements, and traditional retail channels.
Revenue comes from several main sources: the company’s own e-commerce sites, third-party platforms, select distributors and marketing partners, and various brick-and-mortar retailers. This setup reaches both direct consumers and wholesale accounts. The firm competes in the healthcare and consumer wellness space against other CBD producers, supplement brands, and functional beverage companies.
What Draws Investors to YCBD
Investors follow cbdMD because of its position in the CBD and wider wellness industry, where demand for natural and functional health products continues to shift. The portfolio covers CBD, pet wellness, functional mushrooms, THC beverages, and now traditional supplements, giving exposure to several consumer trends at once. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Twinlab acquisition stands out as a longer-term growth element. It brings in long-established brands with existing retail ties and lowers dependence on hemp-derived sales amid regulatory questions. Combined with an emphasis on direct-to-consumer sales and margin focus, this diversification shapes the company’s overall approach.
From a financial standpoint, cbdMD shows traits typical of a small-cap growth company, with a history of net losses while investing in brands and expansion, alongside efforts to reach profitability through cost control and portfolio adjustments. Those watching YCBD pay close attention to revenue growth, gross margin management, and progress toward break-even results.
Key Risks to Consider
Several risks come with investing in cbdMD. The company works in a highly regulated field, so shifts in federal or state rules on hemp, CBD, and THC can significantly affect operations. Recent proposals have included limits on THC content in hemp-derived products, and uncertainty around timing and final details remains a material factor the company has flagged.
Competition is strong from both large consumer brands and smaller CBD and supplement makers. The company’s small scale and record of net losses mean it relies on continued capital access and revenue growth. Additional factors include customer concentration, dependence on wholesale partners, and changes in consumer spending. The CBD and wellness areas also face evolving consumer views and ongoing scientific discussion that can sway demand.
Using Tickeron’s AI Tools in Research
When analyzing companies like cbdMD, I find it helpful to run quick scans with Tickeron’s AI tools to compare performance across the sector and spot relevant patterns. In my view, this adds useful context without replacing deeper fundamental work.
Conclusion
cbdMD, Inc. operates as a small-cap consumer wellness company with a multi-brand lineup that includes CBD, pet products, functional mushrooms, THC beverages, and, after the Twinlab deal, traditional nutritional supplements. Its market stance rests on recognizable brand names, a multi-channel distribution approach, and continued moves to diversify beyond hemp during a period of regulatory change. For those interested in the consumer wellness and CBD sectors, YCBD offers a story closely linked to regulation, brand execution, and movement toward sustainable profitability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
YCBD saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for YCBD moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 33 similar instances where the indicator exited the overbought zone. In 33 of the 33 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
YCBD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Indicator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 86 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for YCBD just turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 148 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.568) is normal, around the industry mean (7.271). P/E Ratio (1.809) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of beauty shops
Industry PharmaceuticalsGeneric
Advertisement